Cargando…
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
BACKGROUND/AIMS: There is controversy about the prophylactic effect of anti-thymocyte globulin (ATG) on graft versus host disease (GVHD) in the setting of matched related-donor hematopoietic stem cell transplantation (HSCT). This study assessed the inf luences of ATG on the incidences of acute and c...
Autores principales: | Ji, Young Sok, Lee, Min Sung, Min, Chang Wook, Park, Seong Kyu, Kim, Se Hyung, Yun, Jina, Kim, Hyun Jung, Kim, Kyoung Ha, Kim, Chan Kyu, Lee, Kyu-Taek, Won, Jong-Ho, Hong, Dae Sik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939503/ https://www.ncbi.nlm.nih.gov/pubmed/27017944 http://dx.doi.org/10.3904/kjim.2015.234 |
Ejemplares similares
-
Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome
por: Choi, Mihong, et al.
Publicado: (2020) -
What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021) -
Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019) -
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017) -
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)